ETF Evaluator: Novo Nordisk A/S (B Shares) ADRhedged () Follow This ETF

Novo Nordisk A/S (B Shares) ADRhedged Overview

Novo Nordisk A/S (B Shares) ADRhedged (NVOH) is an actively managed Sector Equity Health exchange-traded fund (ETF). ADRH launched the ETF in 2025.

The investment seeks to provide investment results that correspond generally, before fees and expenses, to the total return of the ordinary shares of Novo Nordisk A/S (B Shares) in its local market. The series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts (“ADRs”) of the Novo Nordisk A/S (B Shares) (the “Company”). The series will not invest directly in the company. The fund is non-diversified.

About Novo Nordisk A/S (B Shares) ADRhedged (NVOH)

There are 2 members of the management team with an average tenure of 1.56 years: Daniel McCabe (2025) and Mark Criscitello (2025). Management tenure is more important for actively managed ETFs than passive index ETFs.

Novo Nordisk A/S (B Shares) ADRhedged has 6 securities in its portfolio. The top 10 holdings constitute 97.8% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is considered to have an ESG focus with its investment selection and management.

Novo Nordisk A/S (B Shares) ADRhedged is part of the Equity global asset class and is within the Sector Equity ETF group. Novo Nordisk A/S (B Shares) ADRhedged has 97.8% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 0.0% There is 97.8% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Novo Nordisk A/S (B Shares) ADRhedged has 2.2% of the portfolio in cash.

Assets Under Management

The fund has $4 million in total assets, which is below the $1 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.

NVOH Performance and Fees

The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Novo Nordisk A/S (B Shares) ADRhedged expense ratio is low compared to funds in the Health category. Novo Nordisk A/S (B Shares) ADRhedged has an expense ratio of 0.19%, which is 63% lower than its category average, making the fund expense ratio grade a A. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.

High portfolio turnover can translate to higher expenses and lower aftertax returns. Novo Nordisk A/S (B Shares) ADRhedged has a portfolio turnover rate of 0%, which indicates that it holds its assets around /years. By way of comparison, the average portfolio turnover is 45% for the Health category.

Recently, in the month of April 2026, Novo Nordisk A/S (B Shares) ADRhedged returned 12.3%, which earned it a grade of A, as the Health category had an average return of -0.1%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.

Novo Nordisk A/S (B Shares) ADRhedged has a trailing yield of 4.01%, which is above the 1.10% category average. The fund normally distributes its income quarterly and its capital gains annually.

It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.

Novo Nordisk A/S (B Shares) ADRhedged Grades

Year to date, the ETF has returned -14.1%, 23.9 percentage points worse than the category, which translates into a grade of F. The fund has returned -34.1% over the past year (grade of F).

For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.

Otherwise, for more information about Novo Nordisk A/S (B Shares) ADRhedged, including its riskiness, submit your email to unlock the rest of the article.